Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04620330 · ClinicalTrials.gov registry record · Phase 2
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Verastem.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT04620330: Completed Phase 2 study, sponsored by Verastem.
NCT04620330 is a Phase 2 study that has completed, run by Verastem. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04620330, a Phase 2 study, has completed, sponsored by Verastem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.
Primary Outcome
Confirmed overall response rate per RECIST 1.1
Interventions
- DRUG avutometinib (VS-6766)
- DRUG avutometinib (VS-6766) and Defactinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2020-12-31 |
| Est. Completion | 2023-12-12 |
| Phase | Phase 2 |
What the finished NCT04620330 record still lists
NCT04620330 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 2 interventions - of which avutometinib (VS-6766) is the first listed.
NCT04620330 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04620330 about?
NCT04620330 is a clinical study titled "A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer". This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.
What is the current status of trial NCT04620330?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2020-12-31. Estimated completion is 2023-12-12.
What interventions are being tested in trial NCT04620330?
The interventions under investigation include: avutometinib (VS-6766) (DRUG), avutometinib (VS-6766) and Defactinib (DRUG).
Who is sponsoring clinical trial NCT04620330?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04620330's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI